When is NBY's latest earnings report released?
The most recent financial report for Novabay pharmaceuticals, inc. (NBY) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NBY's short-term business performance and financial health. For the latest updates on NBY's earnings releases, visit this page regularly.
Where does NBY fall in the P/E River chart?
According to historical valuation range analysis, Novabay pharmaceuticals, inc. (NBY)'s current price-to-earnings (P/E) ratio is 41.19, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of NBY?
According to the latest financial report, Novabay pharmaceuticals, inc. (NBY) reported an Operating Profit of -1.26M with an Operating Margin of -241.07% this period, representing a decline of 18.38% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is NBY's revenue growth?
In the latest financial report, Novabay pharmaceuticals, inc. (NBY) announced revenue of 521K, with a Year-Over-Year growth rate of -78.66%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does NBY have?
As of the end of the reporting period, Novabay pharmaceuticals, inc. (NBY) had total debt of 970K, with a debt ratio of 0.28. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does NBY have?
At the end of the period, Novabay pharmaceuticals, inc. (NBY) held Total Cash and Cash Equivalents of 2.31M, accounting for 0.66 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does NBY go with three margins increasing?
In the latest report, Novabay pharmaceuticals, inc. (NBY) did not achieve the “three margins increasing” benchmark, with a gross margin of 8.1%%, operating margin of -241.07%%, and net margin of -248.2%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess NBY's profit trajectory and future growth potential.
Is NBY's EPS continuing to grow?
According to the past four quarterly reports, Novabay pharmaceuticals, inc. (NBY)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.22. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of NBY?
Novabay pharmaceuticals, inc. (NBY)'s Free Cash Flow (FCF) for the period is -1.84M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 10.81% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
